Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines

Authors:
  • SGSarah K. Gelehrter
    Sarah K. Gelehrter
  • TVTabitha Vase
    Tabitha Vase
  • RVRajkumar Venkatramani
    Rajkumar Venkatramani
  • WLWendy Landier
    Wendy Landier
  • KWKarla D. Wilson
    Karla D. Wilson
  • CHClaudia Herrera
    Claudia Herrera
  • LRLeah Reichman
    Leah Reichman
  • JMJohn-David Menteer
    John-David Menteer
  • LMLeo Mascarenhas
    Leo Mascarenhas
  • DFDavid R. Freyer
    David R. Freyer
  • KVKalyanasundaram Venkataraman
    Kalyanasundaram Venkataraman

Abstract
Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully elucidated. Metabolomics, the comprehensive profile of small-molecule metabolites, has the potential to provide insight into the pathogenesis of disease states and discover diagnostic markers for therapeutic targets. We performed echocardiographic testing and blood plasma metabolomic analyses (8 pathways; 354 metabolites) in 150 asymptomatic childhood cancer survivors previously treated with anthracyclines. Median time from cancer diagnosis to study participation was 12.4 years (2.6–37.9 years); 64% were treated for a hematologic malignancy; median anthracycline dose was 350 mg/m2 (25–642 mg/m2). Thirty-five (23%) participants had cardiac dysfunction—defined as left ventricular end-systolic wall stress >2SD by echocardiogram. Plasma levels of 15 compounds in three metabolic pathways (carbohydrate, amino acid, and lipid metabolism) were significantly different between individuals with cardiac dysfunction and those with normal systolic function. After adjusting for multiple comparisons, individuals with cardiac dysfunction had significantly lower plasma carnitine levels [relative ratio (RR), 0.89; P < 0.01] in relation to those with normal systolic function. These findings may facilitate the development of primary prevention (treatment of carnitine deficiency before/during anthracycline administration) and secondary prevention strategies (screening and treatment in long-term survivors) in patients at highest risk for CHF. Cancer Epidemiol Biomarkers Prev; 23(6); 1109–14. ©2014 AACR.

This publication has 26 references indexed in Scilit: